Date: September 4, 2026
Country: Croatia
Category: Croatia News / Business & Economy

JGL Secures Long-Term Financing for Its Largest Investment Programme

ZAGREB: Croatian pharmaceutical company Jadran-galenski laboratorij (JGL) has signed a €98.6 million long-term loan agreement with the Croatian Bank for Reconstruction and Development (HBOR), providing financing for the company’s major NEBO investment programme.

The agreement represents an important stage in JGL’s plans to expand its manufacturing and research capabilities. The company said the financing will support improvements to production capacity, technological infrastructure and development facilities.

The NEBO programme, whose name stands for New Era of Boundless Opportunities, is JGL’s largest investment cycle to date. The company has previously put the overall value of the programme at around €139 million.

JGL plans to use the investment to strengthen several parts of its pharmaceutical business, including manufacturing technology, product development, quality systems and research activities.

The company expects the additional capacity to create room for the expansion of existing brands while supporting the development of new products.

International growth is another important objective of the programme. JGL operates in multiple markets, and stronger production and development capabilities could help the company increase its presence outside Croatia.

The loan agreement with HBOR provides a substantial portion of the financing needed for the investment cycle and marks a significant step toward implementation.

JGL has indicated that more detailed information about individual elements of the NEBO programme will be released as the investment progresses.

The development is also notable for Croatia’s industrial sector because it involves a domestic pharmaceutical company directing a major investment toward manufacturing, technology and research.

Why It Matters

The financing could help JGL expand its production and innovation capabilities while strengthening the position of Croatia’s pharmaceutical industry in international markets.